Blueprint Medicines Stock Insider Trading

Healthcare > Biotechnology

Buy BPMC

*Your capital is at risk

$129.46

+0 (+0%)

At Close: Oct 17, 2025

Blueprint Medicines Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -72.66. In total, the insiders bought 235.19K and sold 2.16M BPMC shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-72.66
● Buy	235.19K shares
● Sell	2.16M shares
6% Buy Activity Moderate Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Hewes L. Becker Chief Medical Officer	Officer	19 271 Value: $831.5K
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Hewes L. Becker Chief Medical Officer	Officer	25 000 Value: $2.38M
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Hewes L. Becker Chief Medical Officer	Officer	22 000 Value: $2.12M
Jul 17, 2025 Sell	Common Stock D-Return	Seely Lynn Director	Director	3 902 Value: $0
Jul 17, 2025 Sell	Common Stock U-Tender	Seely Lynn Director	Director	13 254 Value: $0
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Seely Lynn Director	Director	21 818 Value: $416.3K
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Seely Lynn Director	Director	10 909 Value: $213.1K
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Seely Lynn Director	Director	10 909 Value: $502.0K
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Seely Lynn Director	Director	7 500 Value: $523.4K
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Seely Lynn Director	Director	4 875 Value: $471.8K
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Seely Lynn Director	Director	4 500 Value: $343.1K
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Seely Lynn Director	Director	4 500 Value: $392.1K
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Seely Lynn Director	Director	5 300 Value: $268.4K
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Seely Lynn Director	Director	5 300 Value: $337.4K
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Seely Lynn Director	Director	4 570 Value: $485.1K
Jul 17, 2025 Buy	Common Stock A-Award	Carter Percy H. Chief Scientific Officer	Officer	21 353 Value: $2.76M
Jul 17, 2025 Sell	Common Stock D-Return	Carter Percy H. Chief Scientific Officer	Officer	56 614 Value: $0
Jul 17, 2025 Sell	Common Stock U-Tender	Carter Percy H. Chief Scientific Officer	Officer	17 894 Value: $0
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Carter Percy H. Chief Scientific Officer	Officer	39 200 Value: $3.50M
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Carter Percy H. Chief Scientific Officer	Officer	17 500 Value: $1.07M
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Carter Percy H. Chief Scientific Officer	Officer	25 000 Value: $1.08M
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Carter Percy H. Chief Scientific Officer	Officer	25 000 Value: $2.38M
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Carter Percy H. Chief Scientific Officer	Officer	22 000 Value: $2.12M
Jul 17, 2025 Buy	Common Stock A-Award	Rossi Christina Chief Operating Officer	C-Suite Officer	39 456 Value: $5.11M
Jul 17, 2025 Sell	Common Stock D-Return	Rossi Christina Chief Operating Officer	C-Suite Officer	82 374 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BLUEPRINT MEDICINES CORPORATION

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally avail...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by